PegBio Reports No Share Capital Changes, Confirms Public Float Compliance for March 2026

Bulletin Express04-08

PegBio Co., Ltd. (PEGBIO CO-B) submitted its Monthly Return for Equity Issuer, covering the period ended 31 March 2026, with the following highlights:

• Share Capital Stability: Registered share capital remained unchanged at RMB 391.09 million, comprising 284.30 million H shares and 106.79 million unlisted ordinary shares. No new shares were issued, cancelled, or repurchased during the month.

• Issued Shares: Total issued H shares stood at 284.30 million, all of which are in the public market; the company held zero treasury shares. Unlisted ordinary shares remained at 106.79 million.

• Public Float Compliance: PegBio confirmed that its H share public float exceeded the Main Board’s minimum 25% requirement as at 31 March 2026.

• Absence of Dilutive Instruments: The company reported no outstanding share options, warrants, convertible securities, or other agreements that could result in future share issuance.

• Governance: The filing was authorised and submitted by Joint Company Secretary Huang Yifeng on 8 April 2026.

The report indicates a steady capital structure with full compliance to Hong Kong Stock Exchange listing rules and no equity dilution events during the reporting month.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183616961?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-08 17:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183616961","market":"us","top_or_hot":-1,"title":"PegBio Reports No Share Capital Changes, Confirms Public Float Compliance for March 2026","media":"Bulletin Express","content":"<p>PegBio Co., Ltd. (PEGBIO CO-B) submitted its Monthly Return for Equity Issuer, covering the period ended 31 March 2026, with the following highlights:</p>\n<p>• Share Capital Stability: Registered share capital remained unchanged at RMB 391.09 million, comprising 284.30 million H shares and 106.79 million unlisted ordinary shares. No new shares were issued, cancelled, or repurchased during the month.</p>\n<p>• Issued Shares: Total issued H shares stood at 284.30 million, all of which are in the public market; the company held zero treasury shares. Unlisted ordinary shares remained at 106.79 million.</p>\n<p>• Public Float Compliance: PegBio confirmed that its H share public float exceeded the Main Board’s minimum 25% requirement as at 31 March 2026.</p>\n<p>• Absence of Dilutive Instruments: The company reported no outstanding share options, warrants, convertible securities, or other agreements that could result in future share issuance.</p>\n<p>• Governance: The filing was authorised and submitted by Joint Company Secretary Huang Yifeng on 8 April 2026.</p>\n<p>The report indicates a steady capital structure with full compliance to Hong Kong Stock Exchange listing rules and no equity dilution events during the reporting month.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PegBio Reports No Share Capital Changes, Confirms Public Float Compliance for March 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPegBio Reports No Share Capital Changes, Confirms Public Float Compliance for March 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-08 17:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PegBio Co., Ltd. (PEGBIO CO-B) submitted its Monthly Return for Equity Issuer, covering the period ended 31 March 2026, with the following highlights:</p>\n<p>• Share Capital Stability: Registered share capital remained unchanged at RMB 391.09 million, comprising 284.30 million H shares and 106.79 million unlisted ordinary shares. No new shares were issued, cancelled, or repurchased during the month.</p>\n<p>• Issued Shares: Total issued H shares stood at 284.30 million, all of which are in the public market; the company held zero treasury shares. Unlisted ordinary shares remained at 106.79 million.</p>\n<p>• Public Float Compliance: PegBio confirmed that its H share public float exceeded the Main Board’s minimum 25% requirement as at 31 March 2026.</p>\n<p>• Absence of Dilutive Instruments: The company reported no outstanding share options, warrants, convertible securities, or other agreements that could result in future share issuance.</p>\n<p>• Governance: The filing was authorised and submitted by Joint Company Secretary Huang Yifeng on 8 April 2026.</p>\n<p>The report indicates a steady capital structure with full compliance to Hong Kong Stock Exchange listing rules and no equity dilution events during the reporting month.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1183616961","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183616961","pubTimestamp":1775640134,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"PegBio Co., Ltd. (PEGBIO CO-B) submitted its Monthly Return for Equity Issuer, covering the period ended 31 March 2026, with the following highlights: • Share Capital Stability: Registered share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"PegBio报告股本无变化，确认2026年3月公众持股量合规性","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"PegBio Co., Ltd. (PEGBIO CO-B) submitted its Monthly Return for Equity Issuer, covering the period ended 31 March 2026, with the following highlights:\n• Share Capital Stability: Registered share capital remained unchanged at RMB 391.09 million, comprising 284.30 million H shares and 106.79 million unlisted ordinary shares. No new shares were issued, cancelled, or repurchased during the month.\n• Issued Shares: Total issued H shares stood at 284.30 million, all of which are in the public market; the company held zero treasury shares. Unlisted ordinary shares remained at 106.79 million.\n• Public Float Compliance: PegBio confirmed that its H share public float exceeded the Main Board’s minimum 25% requirement as at 31 March 2026.\n• Absence of Dilutive Instruments: The company reported no outstanding share options, warrants, convertible securities, or other agreements that could result in future share issuance.\n• Governance: The filing was authorised and submitted by Joint Company Secretary Huang Yifeng on 8 April 2026.\nThe report indicates a steady capital structure with full compliance to Hong Kong Stock Exchange listing rules and no equity dilution events during the reporting month.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183616961","isCrawlerRequest":true}